Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Guardion Health Sciences, Inc.GHSI · Entity 87936 | Director | June 30, 2023 | July 05, 2023 |
| NOMAD POWER SOLUTIONS, INC.LIXT · Entity 6975 | Vice President and CFO | November 06, 2022 | November 09, 2022 |
| RespireRx Pharmaceuticals Inc.RSPI · Entity 146118 | Director · EVP & Chief Financial Officer | January 18, 2017 | January 20, 2017 |
| Totaligent, Inc.LTMP · Entity 8391 | Chief Financial Officer | July 10, 2017 | July 13, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Guardion Health Sciences, Inc.
Report date June 30, 2023 · Filed July 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.78 · Expires 2028-06-30 | Direct | 334 |
Reported balance
After 2023-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-30 · Grant · Acquired 334 · Balance 334 F1: The option shall vest and become exercisable in eight equal installments on the last day of each of the subsequent eight calendar quarter-end dates following the date of grant (the first of such dates being September 30, 2023), subject to continued service on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become exercisable in eight equal installments on the last day of each of the subsequent eight calendar quarter-end dates following the date of grant (the first of such dates being September 30, 2023), subject to continued service on each vesting date.
NOMAD POWER SOLUTIONS, INC.
Report date November 06, 2022 · Filed November 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2027-11-06 | Direct | 200,000 |
Reported balance
After 2022-11-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-11-06 · Grant · Acquired 200,000 · Balance 200,000 F1: On November 6, 2022, the reporting person was granted options to purchase 200,000 shares of the issuer's common stock, exercisable for a period of 5 years at $2.00 per share, vesting 25% on the issuance date, and 25% on each anniversary date thereafter until fully vested, subject to continued service. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $7.14 · Expires 2025-08-12 | Direct | 58,333 |
Reported balance
Holding disclosure · report date 2022-11-06 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 58,333 |
Filing footnotes · ownership attribution and instrument terms
F1: On November 6, 2022, the reporting person was granted options to purchase 200,000 shares of the issuer's common stock, exercisable for a period of 5 years at $2.00 per share, vesting 25% on the issuance date, and 25% on each anniversary date thereafter until fully vested, subject to continued service.
RespireRx Pharmaceuticals Inc.
Report date January 18, 2017 · Filed January 20, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock Options (to purchase shares of Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $3.90 · Expires 2022-01-18 | Direct | 50,000 |
Reported balance
After 2017-01-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-18 · Grant · Acquired 50,000 · Balance 50,000 F1: These Common Stock Options vest in three installments: 25 percent on January 18, 2017 (the grant date), 25 percent on March 31, 2017, and 50 percent on June 30, 2017. |
| Common Stock Options (to purchase shares of Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $7.38 · Expires 2021-03-31 | Direct | 73,847 |
Reported balance
Holding disclosure · report date 2017-01-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 73,847 F2: The exercise price and number of shares of these securities have been adjusted to reflect the Company's 325-to-1 reverse stock split effective September 1, 2016. F3: These Common Stock Options vested in four equal installments: 25 percent on March 31, 2016 (the grant date), 25 percent on June 30, 2016, 25 percent on September 30, 2016, and 25 percent on December 31, 2016, and are all currently vested and exercisable. |
| Common Stock Options (to purchase shares of Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $6.40 · Expires 2022-08-18 | Direct | 30,770 |
Reported balance
Holding disclosure · report date 2017-01-18 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 30,770 F2: The exercise price and number of shares of these securities have been adjusted to reflect the Company's 325-to-1 reverse stock split effective September 1, 2016. F4: These Common Stock Options vested in four equal installments: 25 percent on December 31, 2015, 25 percent on March 31, 2016, 25 percent on June 30, 2016, and 25 percent on September 30, 2016, and are all currently vested and exercisable. |
| Common Stock Options (to purchase shares of Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $8.13 · Expires 2022-06-30 | Direct | 46,154 |
Reported balance
Holding disclosure · report date 2017-01-18 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 46,154 F2: The exercise price and number of shares of these securities have been adjusted to reflect the Company's 325-to-1 reverse stock split effective September 1, 2016. F5: These Common Stock Options vest in three installments: 50 percent on June 30, 2015, 25 percent on September 30, 2015, and 25 percent on December 31, 2015, and are all currently vested and exercisable. |
| Common Stock Options (to purchase shares of Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $16.25 · Expires 2019-07-17 | Direct | 15,385 |
Reported balance
Holding disclosure · report date 2017-01-18 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 15,385 F2: The exercise price and number of shares of these securities have been adjusted to reflect the Company's 325-to-1 reverse stock split effective September 1, 2016. F6: These Common Stock Options vested in three equal installments on July 17, 2014, September 30, 2014 and December 31, 2014, and are all currently vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: These Common Stock Options vest in three installments: 25 percent on January 18, 2017 (the grant date), 25 percent on March 31, 2017, and 50 percent on June 30, 2017.
F2: The exercise price and number of shares of these securities have been adjusted to reflect the Company's 325-to-1 reverse stock split effective September 1, 2016.
F3: These Common Stock Options vested in four equal installments: 25 percent on March 31, 2016 (the grant date), 25 percent on June 30, 2016, 25 percent on September 30, 2016, and 25 percent on December 31, 2016, and are all currently vested and exercisable.
F4: These Common Stock Options vested in four equal installments: 25 percent on December 31, 2015, 25 percent on March 31, 2016, 25 percent on June 30, 2016, and 25 percent on September 30, 2016, and are all currently vested and exercisable.
F5: These Common Stock Options vest in three installments: 50 percent on June 30, 2015, 25 percent on September 30, 2015, and 25 percent on December 31, 2015, and are all currently vested and exercisable.
F6: These Common Stock Options vested in three equal installments on July 17, 2014, September 30, 2014 and December 31, 2014, and are all currently vested and exercisable.
Totaligent, Inc.
Report date July 10, 2017 · Filed July 13, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| No securities of the Issuer are beneficially ownedSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2017-07-10 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2023 Filed Jul 5, 2023 17:00 UTC | Guardion Health Sciences, Inc. GHSI · Entity 87936 | GrantEmployee Stock Option (right to buy) · Derivative | 334 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001493152-23-023465 · ownership.xml · derivative · entry 1 WEINGARTEN ROBERT N · CIK 0001135337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 334 Underlying: Common Stock · 334 shares Expires 2028-06-30 F1 · derivative.exercise_date: The option shall vest and become exercisable in eight equal installments on the last day of each of the subsequent eight calendar quarter-end dates following the date of grant (the first of such dates being September 30, 2023), subject to continued service on each vesting date. Read SEC document |
| November 06, 2022 Filed Nov 9, 2022 17:00 UTC | NOMAD POWER SOLUTIONS, INC. LIXT · Entity 6975 | GrantStock Options · Derivative | 200,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001493152-22-031140 · ownership.xml · derivative · entry 1 WEINGARTEN ROBERT N · CIK 0001135337 · Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common · 200,000 shares Expires 2027-11-06 F1 · security: On November 6, 2022, the reporting person was granted options to purchase 200,000 shares of the issuer's common stock, exercisable for a period of 5 years at $2.00 per share, vesting 25% on the issuance date, and 25% on each anniversary date thereafter until fully vested, subject to continued service. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 16:10 UTC | Guardion Health Sciences, Inc. GHSI · Entity 87936 | GrantEmployee Stock Option (right to buy) · Derivative | 16,667 | $0.00 Strike: $0.15 | $0.00 |
DisclosureSEC source: 0001493152-22-017373 · ownership.xml · derivative · entry 1 WEINGARTEN ROBERT N · CIK 0001135337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 16,667 shares Expires 2027-06-15 F1 · derivative.exercise_date: The option shall vest and become exercisable in eight equal installments on the last day of each of the subsequent eight calendar quarter-end dates following the date of grant (the first of such dates being September 30, 2022), subject to continued service on each vesting date. Read SEC document |
| August 20, 2021 Filed Aug 23, 2021 06:10 UTC | Guardion Health Sciences, Inc. GHSI · Entity 87936 | GrantCommon Stock, $0.001 par value | 10,000 | $1.14 | $11,400.00 |
DisclosureSEC source: 0001493152-21-020894 · ownership.xml · nonDerivative · entry 1 WEINGARTEN ROBERT N · CIK 0001135337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,750 Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 08:30 UTC | Guardion Health Sciences, Inc. GHSI · Entity 87936 | GrantEmployee Stock Option (right to buy) · Derivative | 16,667 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001493152-21-015932 · ownership.xml · derivative · entry 1 WEINGARTEN ROBERT N · CIK 0001135337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 16,667 shares Expires 2031-06-30 F1 · derivative.exercise_date: The option shall vest and become exercisable in eight equal installments on the last day of each of the subsequent eight calendar quarter-end dates following the date of grant (the first of such dates being September 30, 2021). Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 21:28 UTC | Guardion Health Sciences, Inc. GHSI · Entity 87936 | GrantStock option (right to buy) · Derivative | 250,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001493152-20-016372 · ownership.xml · derivative · entry 1 WEINGARTEN ROBERT N · CIK 0001135337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2030-08-17 F1 · derivative.exercise_date: Subject to the stockholders' approval of an increase in the number of shares available under the Company's 2018 Equity Incentive Plan, 50% of the stock options shall vest on the date of grant and the remaining 50% of the stock options shall vest in equal quarterly installments thereafter until fully vested. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 14:19 UTC | Guardion Health Sciences, Inc. GHSI · Entity 87936 | GrantStock Option · Derivative | 100,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001493152-20-012485 · ownership.xml · derivative · entry 1 WEINGARTEN ROBERT N · CIK 0001135337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-06-30 F1 · derivative.exercise_date: The Option shall vest and become exercisable in eight (8) equal installments on the last day of each of the subsequent eight (8) calendar quarter-end dates following the date of grant (the first of such dates to be September 30, 2020). Read SEC document |
| April 09, 2019 Filed Apr 10, 2019 16:08 UTC | Guardion Health Sciences, Inc. GHSI · Entity 87936 | GrantCommon Stock | 2,500 | $4.00 | $10,000.00 |
DisclosureSEC source: 0001144204-19-019058 · tv518628_form4.xml · nonDerivative · entry 1 WEINGARTEN ROBERT N · CIK 0001135337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 652,500 Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 21:10 UTC | RespireRx Pharmaceuticals Inc. RSPI · Entity 146118 | GrantCommon Stock Options (to purchase shares of Common Stock) · Derivative | 50,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001363763-17-000003 · primary_doc.xml · derivative · entry 1 WEINGARTEN ROBERT N · CIK 0001135337 · Director · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2022-01-18 F1 · derivative.exercise_date: These Common Stock Options vest in three installments: 25 percent on January 18, 2017 (the grant date), 25 percent on March 31, 2017, and 50 percent on June 30, 2017. Read SEC document |
| December 31, 2016 Filed Jan 3, 2017 16:06 UTC | Guardion Health Sciences, Inc. none · Entity 87936 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001135337-17-000001 · primary_doc.xml · nonDerivative · entry 1 WEINGARTEN ROBERT N · CIK 0001135337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300,000 F1 · kind: Grant of restricted stock for services vesting 50% on June 30, 2017 and 50% on December 31, 2017. Read SEC document |
| December 31, 2016 Filed Feb 14, 2017 16:16 UTC Amendment | Guardion Health Sciences, Inc. none · Entity 87936 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001135337-17-000007 · primary_doc.xml · nonDerivative · entry 1 WEINGARTEN ROBERT N · CIK 0001135337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300,000 F1 · kind: The Board of Directors removed the vesting requirement such that the shares vest immediately upon issuance. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.